We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after January 16, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Oral solutions containing leukotriene antagonists
ORAL SOLUTIONS COMPRISING FOLIC ACID
ORAL SOLUTION COMPRISING ATOMOXETINE HYDROCHLORIDE
ESTERS OF STEROIDAL LACTAM AND BIS(2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES
ORAL PHARMACEUTICAL SOLUTIONS CONTAINING HYDROCORTISONE SODIUM PHOSPHATE
METHOD OF DETERMINING PIK3CA MUTATIONAL STATUS IN A SAMPLE
INHIBITION OF ORAL MICROBIAL GROWTH BY A COMPOUND OF PISTACIA LENTISCUS
METHOD FOR THE QUANTIFICATION OFPD-L1